Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07058948 | Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors(SFRT-IM-P2) | recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07556276 | Study of CMTS1215 Injection in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 20 | The Second Hospital of Nanjing Medical UniversityOTHER | 1 | Apr 29, 2026 |
| clinicaltrials |
| NCT05451602 | HEC169096 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 456 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05687682 | Safety of AM-928 Infusion in Advanced Solid Tumors | recruiting | Phase 1 | 38 | AcadeMab Biomedical Inc.INDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06010342 | A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients | recruiting | Phase 2 | 60 | Teligene USINDUSTRY | 2 | Apr 28, 2026 | clinicaltrials |
| NCT06413680 | A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body(BrILliance) | recruiting | Phase 1 / Phase 2 | 240 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07258121 | Study of ZGGS34 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 400 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07413328 | HWS116 Monotherapy in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 56 | Wuhan Humanwell Innovative Drug Research and Development Center Limited CompanyINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06132828 | Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 216 | Zhejiang Doer Biologics Co., Ltd.INDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06227377 | QTX3034 in Patients With KRAS G12D Mutation | recruiting | Phase 1 | 250 | Quanta TherapeuticsINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06723236 | A Study of MGC028 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 124 | MacroGenicsINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07439094 | A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 140 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06801002 | Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies | recruiting | Phase 1 | 25 | Jabez Bioscience, IncINDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06816992 | ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC | recruiting | Phase 1 | 76 | ORIC PharmaceuticalsINDUSTRY | 3 | Apr 24, 2026 | clinicaltrials |
| NCT03810339 | Toripalimab(JS001) as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors | recruiting | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07541573 | GTB-5550 in Advanced Solid Tumors | recruiting | Phase 1 | 175 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05858424 | Impact of a Multidisciplinary End-of-treatment Day Hospital on the Quality of Life of Adolescents and Young Adults With Cancer(HOPAYA) | recruiting | N/A | 214 | Centre Leon BerardOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07020221 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | recruiting | Phase 1 / Phase 2 | 295 | Verastem, Inc.INDUSTRY | 2 | Apr 22, 2026 | clinicaltrials |
| NCT06532565 | Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors | recruiting | Phase 1 | 154 | Gilead SciencesINDUSTRY | 2 | Apr 21, 2026 | clinicaltrials |
| NCT07346846 | A Study of BGM-2121 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 35 | BioGate Precision Medicine Corp.INDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06326411 | A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors(NST-628) | recruiting | Phase 1 | 230 | Nested Therapeutics, IncINDUSTRY | 2 | Apr 20, 2026 | clinicaltrials |
| NCT06892379 | A Study of HS-20110 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 475 | Hansoh BioMedical R&D CompanyINDUSTRY | 2 | Apr 20, 2026 | clinicaltrials |
| NCT07539285 | A Study of HDM2024 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 63 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05865002 | A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1) | recruiting | Phase 1 | 50 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06295965 | Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study | recruiting | — | 2,000 | University of WashingtonOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04879121 | Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06959706 | Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 50 | Tagworks Pharmaceuticals BVINDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07290088 | Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients(PRL3-zumab) | recruiting | Phase 2 / Phase 3 | 52 | Intra-IMMUSG Pte LtdINDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07380334 | A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 200 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT04693377 | Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial | recruiting | N/A | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06799637 | Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments | recruiting | Phase 1 / Phase 2 | 350 | Evopoint Biosciences Inc.INDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06718621 | A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07529002 | Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors | recruiting | — | 20 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03023202 | UWCCC Molecular Tumor Board Registry | recruiting | — | 10,000 | University of Wisconsin, MadisonOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05120596 | First in Human Study of T3P-Y058-739 (T3P) | recruiting | Phase 1 / Phase 2 | 100 | T3 Pharmaceuticals AGINDUSTRY | 3 | Apr 13, 2026 | clinicaltrials |
| NCT05222620 | SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial | recruiting | Phase 2 | 90 | Mayo ClinicOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05423262 | A Study of TRK-950 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 49 | Toray Industries, IncINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06143774 | Study of TRX-920 for Patients With Advanced Solid Tumors | recruiting | Phase 1 | 30 | TaiRx, Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06362369 | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | recruiting | Phase 1 / Phase 2 | 126 | 7 Hills Pharma, LLCINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06487624 | An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors | recruiting | Phase 1 | 50 | FBD Biologics LimitedINDUSTRY | 3 | Apr 13, 2026 | clinicaltrials |
| NCT06709404 | Telehealth Intervention for Improving Distress and Financial Toxicity in the Caregivers | recruiting | N/A | 50 | Wake Forest University Health SciencesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06810544 | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | recruiting | Phase 1 / Phase 2 | 191 | Tango Therapeutics, Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07326488 | A Study of MHB009C in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 200 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03594422 | A Study of HQP1351 in Patients With GIST or Other Solid Tumors | recruiting | Phase 1 | 100 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05178472 | Vertebroplasty With Radiation Therapy for Spine Metastatic Cancer Patients With Indeterminate Lesion (SINS Criteria) | recruiting | N/A | 200 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07192107 | A Study of MHB042C in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 200 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07192120 | A Study of MHB048C in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 200 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT04516447 | A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer(MUIR) | recruiting | Phase 1 | 172 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 7 | Apr 7, 2026 | clinicaltrials |
| NCT05203172 | The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials | recruiting | Phase 4 | 46 | PfizerINDUSTRY | 17 | Apr 7, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Apr 29, 2026source: clinicaltrials